PSA screening in older men: could it save lives?
NCT ID NCT07206693
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at over 257,000 Swedish men aged 75-79 to see if PSA blood tests for prostate cancer reduce deaths. Since no clinical trials have tested this age group, researchers used existing health records to compare screened and unscreened men. The goal is to find out if screening improves survival and whether guidelines should be updated.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PSA test (prostate-specific antigen blood test)
- What this could lead to
- If successful, this could show that PSA screening benefits men aged 75-79, potentially expanding screening guidelines to include this age group.
- What could go wrong
- This is an observational study, not a randomized trial, so results may be influenced by unmeasured factors. It also cannot fully address the risk of overdiagnosis and unnecessary treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Study site
Stockholm, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?